drugset / Trial / NCT04899674

A Study in Healthy Men and Women to Test Whether BI 1358894 Influences the Amount of Bupropion in the Blood

NCT04899674

Phase 1 Completed 18 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The main objective of this trial is to investigate the relative bioavailability of a single dose of bupropion when given alone (Reference) compared with co-administration (Test) with BI 1358894 in healthy volunteers.

Timeline

Start
2021-06-30
Primary completion
2021-09-02
Completion
2021-09-02

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1358894 Small molecule
Subject Bupropion Small molecule

Indications

No indication recorded.